Galmed Pharmaceuticals Ltd., of Tel Aviv, Israel, began screening patients in the U.S. and Latin America for its phase IIb study of aramchol, an oral, arachidic acid-cholic acid conjugate in development for the treatment of nonalcoholic steatohepatitis patients who also suffer from obesity and insulin resistance.